

Marinomed at a glance


Marinomed Biotech AG is an Austrian biopharmaceutical company which was founded in 2006 and is listed on the prime market segment of the **Vienna Stock Exchange (VSE: MARI)**.

Marinomed has the vision to transform the lives of people suffering from diseases with limited or no treatment options in two key therapeutic areas: **virology** and **immunology**.

Marinomed's proprietary technology platforms **Marinosolv®** and **Carragelose®** provide the basis for treating diseases with unmet medical needs.



Business Model



Marinomed focuses on the validation of innovative therapeutic approaches, preclinical and clinical drug development, and subsequent outlicensing to partners. Marinomed's pharmaceutical partner companies handle the late-stage clinical development, regulatory approval and worldwide marketing.

Business Areas

VIROLOGY 

IMMUNOLOGY 

SOLV4U 

Marinomed has an outstanding global track record in the OTC segment with the clinically proven, virus-blocking **Carragelose®**-based products for the prophylaxis and therapy of viral infections of the upper respiratory tract. In addition, Marinomed is developing new treatments for various viral infectious diseases, such as viral pneumonia.

The proprietary **Marinosolv®** technology improves the solubility and bioavailability of hardly soluble small molecules and peptides. This patent-protected technology is applied to R&D projects in immunological indications, which include the lead products **Budesolv** and **Tacrosolv**. Further product candidates for unmet medical needs in immunology are under development.

Marinomed provides **Solv4U technology partnerships** for external customers to address solubility and bioavailability issues and to support the formulation development of drug candidates in all stages of drug discovery based on its innovative Marinosolv® technology platform.

Development pipeline

Therapeutic area	Product Indication	Status	Preclinical	Phase 1	Phase 2	Phase 3	Filing/ Certification
IMMUNOLOGY	Budesolv/MAM-1004-1 Allergic rhinitis	Filing in preparation	[Progress bar]				
	Tacrosolv/MAM-1003-1 Inflammatory eye diseases	Phase 2 clinical study	[Progress bar]				
	MAM-1004-2 Autoimmune gastritis	Preclinical	[Progress bar]				
VIROLOGY	Carravin/MAM-2001-1 Nasal congestion	Filing in progress	[Progress bar]				
	Inhaleen/MAM-1001-1 Viral pneumonia	Phase 1 clinical study	[Progress bar]				

Commercialized products

VIROLOGY	Carragelose product portfolio Viral respiratory infections	Portfolio of seven different products (nasal & throat sprays, lozenges), marketed in >40 countries
----------	--	--

Sustainability

Sustainable management is part of Marinomed's corporate strategy. Marinomed's mission is to improve the health of patients in the long term. We want to achieve this by developing innovative and more effective therapies. Our sustainability goals also include the protection of the environment and climate as well as diversity, the search for strong partnerships and much more.



Follow us on  @Marinomed Biotech AG  @Marinomed_AG

Please contact our Business development team at:
bd@marinomed.com | +43 2262 90300

 Marinomed Biotech AG
Hovengasse 25, 2100 Korneuburg, Austria

www.marinomed.com

